An archived copy of the webcast will be available for up to one year on the “Investors ... transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, ...

D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment ...

GoDaddy Inc.  Chief Financial Officer Mark McCaffrey will present at the 53rd Annual J.P. Morgan Global Technology, Media and Communications Conference in Boston, Massachusetts on Tuesday, May 13, ...

MongoDB’s $220 million Voyage AI deal is the only major acquisition in the company’s history. We expect the acquisition of Voyage AI to more than triple MongoDB’s goodwill balance of $70 million as of ...

[Operator Instructions] To note, there is an accompanying earnings deck presentation available on the IBEX Investor Relations website at ... of our powerful new logo sales engine winning large ...

EMERYVILLE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted ...

Our second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with ... Therapeutic ...

By Dhwani Pandya, Praveen Paramasivam, Ruma Paul and Manoj Kumar TIRUPPUR, India/DHAKA, Bangladesh (Reuters) -In a garment ...

Enrolled first patients in first 4D-150 Phase 3 clinical trial (4FRONT-1) in wet AMD, with over 50 clinical trial sites open to dateInitiation of second 4D-150 Phase 3 clinical trial (4FRONT-2) expect ...

This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of ...